Ms. Ref. No.

: MSARD-D-21-01007
Title: “Humoral and T-Cell Responses to SARS-CoV-2 Vaccination in Multiple
Sclerosis Patients Treated with Ocrelizumab”
Multiple Sclerosis and Related Disorders

Dear Dr. Barbara Barun,

Given your expertise in this research area, we would appreciate your

comments on the paper entitled "“Humoral and T-Cell Responses to SARS-
CoV-2 Vaccination in Multiple Sclerosis Patients Treated with Ocrelizumab”".

If you accept this invitation, your comments will be due within 21 days. If you
are unable to act as a reviewer at this time, we would greatly appreciate your
suggestions for alternate reviewers.

If you are willing to review this manuscript, please click on the link below:

https://www.editorialmanager.com/msard/l.asp?i=172286&l=JHOG5CYI

If you are unable to review, please click on the link below. You will have an
opportunity to write a message to the Editor, or to suggest alternative
reviewers.
https://www.editorialmanager.com/msard/l.asp?i=172287&l=XEX34HDV

Alternatively, you may register your response by accessing the Editorial

Manager for Multiple Sclerosis and Related Disorders as a REVIEWER using
the login credentials below:
https://www.editorialmanager.com/msard/
Your username is: barbarabarun@gmail.com
If you need to retrieve password details, please go to: https://
www.editorialmanager.com/msard/l.asp?i=172288&l=5XU5I1UG
In addition to accessing our subscriber content, you can also use our Open
Access content. Read more about Open Access here: http://
www.elsevier.com/openaccess

Upon submission of your review report to the system, you will get access to
your personalized Elsevier reviews profile page as well as the possibility of
creating a public page listing your reviews across all publishers in just a few
steps! See http://www.reviewerrecognition.elsevier.com and http://
www.reviewerpage.com for more information.

As a reviewer you are entitled to complimentary access to references,

abstracts, and full-text articles on ScienceDirect and Scopus for 30 days.
Full details on how to claim your access via Reviewer Hub
(reviewerhub.elsevier.com) will be provided upon your acceptance of this
invitation to review.

Please visit the Elsevier Reviewer Hub (reviewerhub.elsevier.com) to manage

all your refereeing activities for this and other Elsevier journals on Editorial
Manager.

We look forward to hearing from you in the near future.

Yours sincerely,
Please also note that authors have been invited to convert their
supplementary material into a Data in Brief article (a data description
article). You may notice this change alongside the revised manuscript. You
do not need to review this, but may need to look at the files in order to
confirm that any supporting information you requested is present there.
Michael Levy, MD, PhD
Managing Editor
Multiple Sclerosis and Related Disorders

*****

Please also note that authors have been invited to convert their
supplementary material into a Data in Brief article (a data description
article). You may notice this change alongside the revised manuscript. You
do not need to review this but may need to look at the files in order to
confirm that any supporting information you requested is present there.

******************************************
For further assistance, please visit our customer support site at http://
help.elsevier.com/app/answers/list/p/7923. Here you can search for solutions
on a range of topics, find answers to frequently asked questions and learn
more about EM via interactive tutorials. You will also find our 24/7 support
contact details should you need any further assistance from one of our
customer support representatives.

Please note: Reviews are subject to a confidentiality policy,

http://service.elsevier.com/app/answers/detail/a_id/14156/supporthub/
publishing/

#REV_MSARD#

To ensure this email reaches the intended recipient, please do not delete the
above code

__________________________________________________
In compliance with data protection regulations, you may request that we
remove your personal registration details at any time. (Use the following
URL: https://www.editorialmanager.com/msard/login.asp?a=r). Please
contact the publication office if you have any questions.